Marriage Of Kite’s CAR-T Platform To Amgen Targets Will Expand Pipeline For Both
This article was originally published in The Pink Sheet Daily
Executive Summary
Kite’s initial partnership with another biopharma sees it bringing its CAR-T platform technology to bear on Amgen’s oncology targets. Each company could develop new cancer immunotherapy products out of the collaboration, with earn-outs for the other.